JKN23061

JKN23061 is a small molecule inhibitor of the voltage-gated sodium channel Nav1.8 (encoded by the SCN10A gene), developed by Guangzhou Fermion Technology Co., Ltd. for the treatment of pain. Nav1.8 is primarily expressed in peripheral sensory neurons (nociceptors) and plays a critical role in the transmission of pain signals. By selectively blocking Nav1.8, JKN23061 aims to provide potent analgesia for acute and chronic pain conditions while avoiding the central nervous system and cardiovascular side effects associated with non-selective sodium channel blockers or the addiction risks of opioids. The drug is designed for high selectivity and potency, and it is currently undergoing early-phase clinical evaluation to determine its safety, tolerability, and pharmacokinetic profile.